Clinical Trial Detail

NCT ID NCT02574533
Title Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Gradalis, Inc.
Indications

melanoma

Therapies

Pembrolizumab

FANG vaccine

Age Groups: adult

No variant requirements are available.